Larissa Podust, PhD, is working on a new drug for Chagas disease, a neglected scourge.
July 15, 2010
A diabetes-care program designed by clinical pharmacy faculty in the UCSF School of Pharmacy Center for Self-Care has just launched in Northern California as a service for members of the California Public Employees Retirement System (CalPERS) with Blue Shield health coverage.
July 02, 2010
Antibiotic-resistant Staph infection is not the only emerging bacterial threat. Now a different bug -- Clostridium difficile -- is gaining strength.
June 16, 2010
James McKerrow, leader of the Sandler Center for Drug Discovery at UCSF, was honored with the 2009 Mendel Medal for his work identifying the vulnerabilities of disease-causing parasites and for devising new strategies to fight them.
April 22, 2010
Insight into pneumonia deaths due to antibiotic-resistant Staphylococcus aureus infections emerges from UCSF study.
March 19, 2010
The UCSF School of Pharmacy is charting new territory with an interdisciplinary education program for health care professionals on Medicare Part D.
March 18, 2010
Taking an innovative path toward personalized medicine, scientists for the first time will be able to eliminate – at an early point in a clinical trial — experimental drugs that show poor efficacy, dramatically shortening the time it takes to get the right medication to the right patient with breast cancer.
March 03, 2010
New UCSF clinical trial tests intermittent high-dosage treatment for HER2-positive breast cancers.
March 01, 2010
A panel of experts appointed by Mayor Gavin Newsom recently presented an action plan as the approaching “age wave may bring a potential crisis in Alzheimer’s and dementia care” to San Francisco.
February 19, 2010
UCSF nephrologist Flavio Vincenti, MD, is the lead author of a paper in the March 2010 issue of the American Journal of Transplantation that reports results from a Phase III clinical trial for a new drug that selectively blocks immune suppression for kidney transplants. The drug, belatacept, is given to kidney-transplant recipients to prevent the immune system from rejecting the new organ. Vincenti and his co-investigators found that belatacept may be as effective as the commonly used anti-rejection drug cyclosporine, but with fewer side effects and superior kidney function after 12 months.